177 Lutetium PSMA 617 - Endocyte

Drug Profile

177 Lutetium PSMA 617 - Endocyte

Alternative Names: 177LU-PSMA-617 - Endocyte

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte; RadioMedix
  • Developer Australian Nuclear Science and Technology Organisation
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 06 Nov 2017 Endocyte and Radiomedix entered into agreement for the transfer of the US IND of 177-Lu-PSMA-617
  • 06 Nov 2017 Endocyte, The University of Sydney and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaborate for the planned phase II TheraP trial
  • 06 Nov 2017 Adverse events data from a phase I/II trial in Prostate cancer released by Endocyte
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top